Regenerative medicine company Avita Medical, Inc. (ASX: AVH) has been awarded a group purchasing agreement with Premier, Inc. covering its s point-of-care autologous skin restoration product, RECELL.
The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the RECELL System for the treatment of adult and paediatric patients that require treatment for severe burns.
The RECELL System is a device that enables healthcare professionals to produce a suspension of Spray-On Skin Cells using a small sample of the patient’s own skin for the treatment of acute thermal burns.
“When someone experiences a severe burn injury, time matters, and that is why this agreement with Premier is so important – it will help ensure that patients in need of treatment are able to efficiently and effectively access the RECELL System without delay,” said Dr Mike Perry, AVITA Medical’s Chief Executive Officer.
“As a leading GPO, Premier is a trusted partner among their alliance of members and AVITA Medical is committed to building on that trust by providing quality products to help ensure the best patient care possible.
“This agreement represents a major milestone for AVITA Medical as it puts our innovative RECELL System into the hands of those caring for burn patients across the U.S.”
This new agreement enables AVITA Medical access to Premier’s member hospitals and regional representatives to help facilitate the adoption of the RECELL System into their facilities.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 225,000 other providers to transform healthcare.
With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost that is developing and commercialising a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that they have been awarded a group purchasing agreement with Premier, Inc.
AVITA Medical’s first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns.
The system is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required.
The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomised, controlled clinical trials conducted at major U.S. burn centres and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.
Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
